Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway Masp-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects

Category Primary study
JournalBlood
Year 2022
This article has no abstract
Epistemonikos ID: d847919348b18aefcabcf15d9bf63c7e9cc786a4
First added on: Apr 29, 2024